The GLP-1 receptor (GLP-1R) is an established drug target for the treatment of diabetes and obesity 2 , whereas the therapeutic potential of the GIP receptor (GIPR) is a subject of debate
Do not initiate or discontinue any therapy based on this article without consultation with a qualified healthcare professional
Structural studies using cryogenic electron microscopy have further shown that Cagrilintide stabilizes active receptor conformations that support downstream signaling through G protein coupled receptor pathways
However, the causal relationships among microbial dysbiosis, immune dysregulation, and disease onset remain elusive
GIP has been shown to decrease food intake while blunting the metabolic adaptive responses that usually occur with calorie restriction resulting in weight reductions, and when combined with GLP-1 receptor agonism, may result in greater effects on markers of metabolic dysregulation such as body weight, glucose and lipids
Kelly B, Pearce EL